Shipping delays may occur due to increased holiday volume. Please order early or upgrade shipping for timely delivery.
Until recently, a diagnosis of Feline Infectious Peritonitis (FIP) has been a grim verdict for kittens and young adult cats, especially in shelters and multi-cat environments. But today, there's a new hope on the horizon.
Wedgewood is proud to introduce a compounded version of molnupiravir—available in both a custom-flavored oral oil suspension and precisely dosed capsules. Independent studies of commercially available molnupiravir, which is a different formulation than Wedgewood's formulation, have shown that using a 12-week treatment protocol is turning the tide against FIP and bringing new hope to affected felines and their families.
"A newer therapeutic option, is being used as a first line therapy for FIP and as a rescue therapy to treat cats who have persistent or relapsed clinical signs of FIP after GS-441524."
-Roy, et al., "Unlicensed Molnupiravir is an Effective Rescue Treatment Following Failure of Unlicensed GS-441524-like Therapy for Cats with Suspected Feline Infectious Peritonitis"
Key Facts
Available in Two Dosage Forms:
- Flavored Oral Oil Suspension: Customizable flavors for easy administration and compliance.
Capsules: Available in various strengths, tailored for your cat’s unique needs.
How It Works: Prior independent studies (linked below) of the generic version have shown that it interferes with the FIP virus's ability to replicate, slowing disease progression and allowing for the resolution of symptoms.*
Dosage and Administration: Dosing varies from 10mg/kg, 12mg/kg, 15mg/kg, and 20mg/kg twice per day based on the weight of the cat and the type of FIP – Effusive, Non-Effusive, Ocular, or Neurological.
Side Effects: According to these independent studies, side effects are mild, making molnupiravir a good choice for first-line treatment, as well as second-line treatment if other treatments fail.
Dating: The Beyond-Use Dating for Wedgewood’s molnupiravir is up to 90 days for the oral solution and 180 days for the capsules.
*We note that Wedgewood’s formulation containing molnupiravir has not been studied in any clinical trials. Wedgewood makes no claims of safety or efficacy with respect to the medications it produces and sells. The information provided herein is for informational purposes only.
Independent Third-Party Studies
Some practitioners may find the studies which we provide below useful. The medications used in the studies were not provided by Wedgewood Pharmacy and we make no claim that the results found in the studies have any connection with or relevance to the results that may be achieved with any Wedgewood Pharmacy drug. The authors of this study are not endorsing in any manner any Wedgewood Pharmacy product and any implication to the contrary is expressly denied.
Dosing Calculator
There are two dosing protocols based on independent clinical studies. Refer to the dosing calculator to easily find the correct dose. Just select your preferred protocol, the form of FIP in the affected cat, and the cat’s weight to receive a dosing recommendation.
"In our series of casts with presumptive FIP treated with an off label compounded formulation of molnupiravir, 14 out of 18 cats achieved remission and remained in remission at the time of writing, during up to 107 days of follow up."
-Okihiro Sase, "Molnupiravir treatment of 18 cats with feline infectious peritonitis: A case series"
Compounded Molnupiravir Preparations
Additional Resources
The Evolution of FIP Treatment
Understanding Compounded Molnupiravir and Its Role in Treating Feline Infectious Peritonitis
This RACE-approved course offers a comprehensive look at FIP, exploring it's various presentations and treatment options. By the end of this session, you'll be equipped to integrate compounded molnupiravir into your treatment arsenal, improving patient outcomes.
FAQs
Is molnupiravir better than GS-441524 for FIP in cats?
Research shows that molnupiravir can work both as a first-line rescue therapy as well as a secondary line of therapy when symptoms persist or relapse after initially treating with GS-441524.
Is molnupiravir FDA-approved for cats?
The FDA has not approved molnupiravir for animal use but has authorized it for human treatment of mild to moderate COVID-19 in high-risk patients. However, multiple studies suggest it's a safe and effective option for treating FIP in cats.
Can my practice order molnupiravir for office stock?
Molnupiravir was nominated to the FDA’s list of office stock drugs and is currently under review, per GFI #256. This means that molnupiravir can be sold to hospitals for office stock in all states except Hawaii, Montana, New York, Oregon, Rhode Island, South Dakota, and Washington D.C. Veterinarians who work in a state that does not allow USP compounded medications for office stock can prescribe molnupiravir in a patient’s name.
How long will it take for an order or prescription for molnupiravir to ship, and how long will it spend in transit?
Orders for molnupiravir are expected to ship within 1-2 business days. Time in transit will depend on the shipping method chosen.
Do you ship internationally?
We ship to all 50 states, Puerto Rico, the US Virgin Islands, Canada, Guam, and all US military bases worldwide.
What is the Beyond-Use Dating (BUD) for molnupiravir?
The oral liquids will have a 90-day BUDs from the date of compounding. The capsules will have 180 days from the day of compounding.
Where can I find more information?
For more information, we invite you to read these recent studies:
Molnupiravir treatment of 18 cats with feline infectious peritonitis: a case series | Sase
*The medications used in the studies were not provided by Wedgewood Pharmacy and we make no claim that the results found in the studies have any connection with or relevance to the results that may be achieved with any Wedgewood Pharmacy drug. The authors of these studies are not endorsing in any manner any Wedgewood Pharmacy product and any implication to the contrary is expressly denied.
*We note that Wedgewood’s formulation containing molnupiravir has not been studied in any clinical trials. Wedgewood makes no claims of safety or efficacy with respect to the medications it produces and sells. The information provided herein is for informational purposes only.